Contextlogic Holdings Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Contextlogic Holdings Inc (LOGC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Contextlogic Holdings Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 16M vs 4,130M combined for tracked competitors (0.4% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+754.3% annualized vs trailing 12 months), vs accelerating (+8.5%) for its tracked peer group.
- Profitability: Its -18.8% net margin compares with -42.4% for the peer group.
- Scale: Contextlogic Holdings Inc ranks #20 of 36 companies by market capitalization in the Internet, E-commerce, Online Shops industry, holding 0.0% of industry market cap.
- Peer revenue share: Contextlogic Holdings Inc accounted for 2.9% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $0.04M compares with $0.76M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
LOGC Sales vs. its Competitors, Q2 2026
With a net margin of -18.75 %, Contextlogic Holdings Inc achieved higher profitability than its competitors (-42.37 %).
Contextlogic Holdings Inc generated 2.91 % of the combined sales of its peer group.
Contextlogic Holdings Inc vs. its Competitors, Q2 2026
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Contextlogic Holdings Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Contextlogic Holdings Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Contextlogic Holdings Inc's competitor groups requires a Commercial License.
Contextlogic Holdings Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Contextlogic Holdings Inc | - | - | - | - |
| Competitors combined (30) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
LOGC Stock Performance relative to its Competitors
LOGC Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Century Therapeutics inc | 282.9% | Outperformed |
| 2 | Krystal Biotech Inc | 282.9% | Outperformed |
| 3 | 4d Molecular Therapeutics Inc | 282.9% | Outperformed |
| 4 | Tectonic Therapeutic Inc | 282.9% | Outperformed |
| 5 | Taysha Gene Therapies Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Contextlogic Holdings Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Contextlogic Holdings Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Contextlogic Holdings Inc | 688.80 | 15.73 |
| Krystal Biotech Inc | 10,333.86 | 440.48 |
| Crispr Therapeutics Ag | 5,220.45 | 13.39 |
| Beam Therapeutics Inc | 2,527.84 | 156.04 |
| Sarepta Therapeutics Inc | 1,982.10 | 1,974.34 |
| Taysha Gene Therapies Inc | 1,841.53 | 8.10 |
| SUBTOTAL | 31,212.80 | 4,283.86 |
Sign in to see all competitors of Contextlogic Holdings Inc .
Sources: Contextlogic Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Contextlogic Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Contextlogic Holdings Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Sarepta Therapeutics Inc | All Other Segments 100.00 % |
| Immunocore Holdings Plc | Reportable 100.00 % |
| Ginkgo Bioworks Holdings Inc | Reportable 100.00 % |
| Prime Medicine Inc | Reportable 100.00 % |
| Century Therapeutics inc | Single reportable segment 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Contextlogic Holdings Inc .
Contextlogic Holdings Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Contextlogic Holdings Inc | 689 | 39,330 | 128,500 |
| Krystal Biotech Inc | 10,334 | 1,493,166 | 818,525 |
| Crispr Therapeutics Ag | 5,220 | 66,627 | -2,244,473 |
| Beam Therapeutics Inc | 2,528 | 305,352 | -167,176 |
| Sarepta Therapeutics Inc | 1,982 | 2,364,484 | -8,798 |
| Taysha Gene Therapies Inc | 1,842 | 81,798 | -1,511,444 |
| PEERS TOTAL | 30,524 | 756,493 | -420,584 |
Sign in to see all peers for Contextlogic Holdings Inc .
Contextlogic Holdings Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Krystal Biotech Inc | United States 75.19 % |
| 4d Molecular Therapeutics Inc | JP 97.05 % |
| Caribou Biosciences Inc | United States 94.16 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Contextlogic Holdings Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 32 companies in Contextlogic Holdings Inc's industry classification, broader than the peer set above. Market cap in millions of $.Contextlogic Holdings Inc ranks #20 of 32 companies by market capitalization in its industry, holding 0.01 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 9,402, indicating a highly concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amazon com Inc | 2,683,773 | 96.96 % |
| 2 | Coupang Inc | 24,736 | 0.89 % |
| 3 | Cdw Corp | 16,604 | 0.60 % |
| 4 | Wayfair inc | 13,019 | 0.47 % |
| 5 | Chewy Inc | 1,234 | 5.2% |
| 6 | Insight Enterprises Inc | 1,234 | 5.2% |
| 7 | Pattern Group Inc | 1,234 | 5.2% |
| 8 | Pc Connection Inc | 1,234 | 5.2% |
| 9 | Gigacloud Technology Inc | 1,234 | 5.2% |
| 10 | Revolve Group Inc | 1,234 | 5.2% |
| 20 | Contextlogic Holdings Inc | 288 | 0.01 % |
Market cap and industry share for the rest of Contextlogic Holdings Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Contextlogic Holdings Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 15 | Betterware De M Xico S A P I De C V | 632 | 30.07 % |
| 16 | Lightinthebox Holding Co Ltd | 619 | 49.51 % |
| 17 | The Honest Company Inc | 599 | 38.33 % |
| 18 | Baozun Inc | 535 | -27.70 % |
| 19 | Stitch Fix Inc | 1,234 | 12.3% |
| 20 | Contextlogic Inc | 288 | 84.61 % |
| 21 | Thredup Inc | 1,234 | 12.3% |
| 22 | 1stdibs com Inc | 1,234 | 12.3% |
| 23 | Global Ai Inc | 1,234 | 12.3% |
| 24 | A k a Brands Holding Corp | 1,234 | 12.3% |
| 25 | Able View Global Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Contextlogic Holdings Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Contextlogic Holdings Inc's Valuation vs Competitive Position
Valuation multiples vs the Internet, E-commerce, Online Shops industry average (50 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 18.4x | - |
| EV / EBITDA | - | 14.3x | - |
| P/B | 0.9x | 3.2x | -2.3x |
| Return on Equity | 26.89 % | industry aggregate | -3.36 % |
| Return on Invested Capital | -3.46 % | 4.58 % (avg) | -8.04 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Contextlogic Holdings Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | -77.53 % | -49.74 % | - |
| Operating Margin | - | -119.35 % | -69.70 % | -114.29 % | - |
| Return on Invested Capital | -58.27 % | -169.07 % | -31.67 % | -52.13 % | -33.13 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Contextlogic Holdings Inc's BCG Growth-Share Matrix
Relative market share (vs Contextlogic Holdings Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Contextlogic Holdings Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 3.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution. A caveat worth reading alongside this chart: Amazon com Inc alone holds 97% of this industry's market cap. In an industry this dominated by one leader, the framework will place nearly every OTHER company in "Dog" or "Question Mark" purely because relative share is measured against that leader, regardless of how strong those other companies actually are on their own fundamentals. Check the Profitability, Valuation and Financial Strength sections above before treating this quadrant label as a verdict.
Contextlogic Holdings Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Low | Industry HHI of 9,402 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Contextlogic Holdings Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Contextlogic Holdings Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Contextlogic Holdings Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Contextlogic Holdings Inc falls in the Medium attractiveness / Low strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Contextlogic Holdings Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+754.3% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Low relative market share vs the industry leader (0.00x).
Opportunities
- A meaningful share of tracked competitors (57.10 %) show financial-distress signals, a possible opening to gain share.
Threats
- Industry dominated by Amazon com Inc , holding 96.96 % of industry market cap.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Contextlogic Holdings Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Contextlogic Holdings Inc | 7.54 | 18.49 | 0.25 |
| Krystal Biotech Inc | 5.21 | 9.38 | - |
| Crispr Therapeutics Ag | 2.51 | 16.26 | 0.16 |
| Beam Therapeutics Inc | 4.72 | 11.07 | 0.05 |
| Sarepta Therapeutics Inc | 0.81 | 3.24 | 0.48 |
| Taysha Gene Therapies Inc | 13.32 | 13.51 | 0.19 |
Sign in to see all peers for Contextlogic Holdings Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Contextlogic Holdings Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Contextlogic Holdings Inc | Q2 2026 | - | - |
| Krystal Biotech Inc | Q2 2026 | +24.1 % | +42.9 % |
| Crispr Therapeutics Ag | Q2 2026 | +1,041.4 % | - |
| Beam Therapeutics Inc | Q2 2026 | -94.2 % | - |
| Sarepta Therapeutics Inc | Q2 2026 | -34.3 % | - |
| Taysha Gene Therapies Inc | Q2 2026 | - | - |
| PEERS TOTAL | +24.1 % | - |
Sign in to see all peers for Contextlogic Holdings Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Contextlogic Holdings Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Contextlogic Holdings Inc | Q2 2026 | - | - |
| Krystal Biotech Inc | Q2 2026 | - | +87.2 % |
| Crispr Therapeutics Ag | Q2 2026 | - | +453.8 % |
| Beam Therapeutics Inc | Q2 2026 | - | -23.0 % |
| Sarepta Therapeutics Inc | Q2 2026 | - | -98.3 % |
| Taysha Gene Therapies Inc | Q2 2026 | - | - |
Sign in to see all peers for Contextlogic Holdings Inc .
Contextlogic Holdings Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Contextlogic Holdings Inc | 8.00% | 6.17% | 11.74% |
| Krystal Biotech Inc | 17.65% | 19.16% | 19.34% |
| Crispr Therapeutics Ag | - | - | - |
| Beam Therapeutics Inc | - | - | - |
| Sarepta Therapeutics Inc | - | - | - |
| Taysha Gene Therapies Inc | - | - | - |
Sign in to see all peers for Contextlogic Holdings Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Contextlogic Holdings Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Contextlogic Holdings Inc | - | 43.78 |
| Krystal Biotech Inc | 42.14 | 23.46 |
| Crispr Therapeutics Ag | - | 389.82 |
| Beam Therapeutics Inc | - | 16.20 |
| Sarepta Therapeutics Inc | - | 1.00 |
| Taysha Gene Therapies Inc | - | 227.41 |
| PEERS AVERAGE | - | 7.29 |
Sign in to see all peers for Contextlogic Holdings Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.